NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T1AM treatment

Authors

  • J.A. Haviland,

    1. Department of Zoology, University of Wisconsin-Madison, Madison, Wisconsin, USA
    Search for more papers by this author
  • H. Reiland,

    1. Department of Biochemistry, Madison, Wisconsin, USA
    Search for more papers by this author
  • D.E. Butz,

    1. Department of Zoology, University of Wisconsin-Madison, Madison, Wisconsin, USA
    Search for more papers by this author
    • Disclosure: The authors declare competing financial interests. Authors F.M.A.P., D.E.B., M.T., and W.P.P. are cofounders of Isomark LLC.

  • M. Tonelli,

    1. National Magnetic Resonance Facility at Madison, Universtiy of Wisconsin, Madison, Wisconsin, USA
    Search for more papers by this author
    • Disclosure: The authors declare competing financial interests. Authors F.M.A.P., D.E.B., M.T., and W.P.P. are cofounders of Isomark LLC.

  • W.P. Porter,

    1. Department of Zoology, University of Wisconsin-Madison, Madison, Wisconsin, USA
    Search for more papers by this author
    • Disclosure: The authors declare competing financial interests. Authors F.M.A.P., D.E.B., M.T., and W.P.P. are cofounders of Isomark LLC.

  • R. Zucchi,

    1. Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Università di Pisa, Pisa, Italy
    Search for more papers by this author
  • T.S. Scanlan,

    1. Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, Oregon, USA
    2. Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, Oregon, USA
    Search for more papers by this author
  • G. Chiellini,

    Corresponding author
    1. Department of Biochemistry, Madison, Wisconsin, USA
    2. Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Università di Pisa, Pisa, Italy
    Search for more papers by this author
  • F.M. Assadi-Porter

    Corresponding author
    1. Department of Biochemistry, Madison, Wisconsin, USA
    2. National Magnetic Resonance Facility at Madison, Universtiy of Wisconsin, Madison, Wisconsin, USA
    Search for more papers by this author
    • Disclosure: The authors declare competing financial interests. Authors F.M.A.P., D.E.B., M.T., and W.P.P. are cofounders of Isomark LLC.


  • Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author notes may be found in the online version of this article.

    Funding agencies: This research was supported by the Rodale Foundation, the Farmers Advocating for Organics (FAFO) fund, grant R01 DC009018 from NIH, and the Wisconsin Institute of Discovery Grant (WID-135A039). This work was supported in part by funds from the following: the Rodale Foundation; the Farmers Advocating for Organics (FAFO) fund to W.P.P.; grants R01 DC009018 from NIH; the Wisconsin Institute of Discovery Grant (WID-135A039) to F.M.A.P. This study made use of the National Magnetic Resonance Facility at Madison, which is supported by NIH grants P41RR02301 (BRTP/ NCRR) and P41GM66326 (NIGMS). Additional equipment was purchased with funds from the University of Wisconsin, the NIH (RR02781, RR08438), the NSF (DMB-8415048, OIA-9977486, BIR-9214394), and the USDA.

Abstract

Objective

3-Iodothyronamine (T1AM), an analog of thyroid hormone, is a recently discovered fast-acting endogenous metabolite. Single high-dose treatments of T1AM have produced rapid short-term effects, including a reduction of body temperature, bradycardia, and hyperglycemia in mice.

Design and Methods

The effect of daily low doses of T1AM (10 mg/kg) for 8 days on weight loss and metabolism in spontaneously overweight mice was monitored. The experiments were repeated twice (n = 4). Nuclear magnetic resonance (NMR) spectroscopy of plasma and real-time analysis of exhaled 13CO2 in breath by cavity ring down spectroscopy (CRDS) were used to detect T1AM-induced lipolysis.

Results

CRDS detected increased lipolysis in breath shortly after T1AM administration that was associated with a significant weight loss but independent of food consumption. NMR spectroscopy revealed alterations in key metabolites in serum: valine, glycine, and 3-hydroxybutyrate, suggesting that the subchronic effects of T1AM include both lipolysis and protein breakdown. After discontinuation of T1AM treatment, mice regained only 1.8% of the lost weight in the following 2 weeks, indicating lasting effects of T1AM on weight maintenance.

Conclusions

CRDS in combination with NMR and 13C-metabolic tracing constitute a powerful method of investigation in obesity studies for identifying in vivo biochemical pathway shifts and unanticipated debilitating side effects.

Ancillary